GSK’s Game-Changing Move
Senator Bernie Sanders applauded GSK’s recent decision to cap out-of-pocket costs for eligible patients at a maximum of $35 per month for asthma and COPD medications. Effective by January 1, 2025, this move is expected to provide significant relief to numerous Americans in need of these vital medicines.
Competitive Response
Following GSK’s lead, AstraZeneca also pledged to limit monthly expenses for U.S. patients to $35 starting June 1, 2024. This echoes a broader industry trend towards making essential treatments more affordable and accessible.
Government Intervention
Earlier this year, the HELP Committee scrutinized major inhaler manufacturers, criticizing them for stark price discrepancies between the U.S. and other countries. These investigations shed light on the substantial revenue generated by companies like AstraZeneca, GSK, and Teva from inhaler sales.
International Disparities
The committee highlighted examples such as GSK’s pricing of Advair HFA at $319 in the U.S., sharply contrasting with the $26 cost in the U.K. Similarly, Teva’s QVAR RediHaler costs $286 for U.S. patients but a mere $9 in Germany, showcasing the significant price differentials.
Market Impact
Amid these developments, GSK shares saw a modest increase of 0.12% during the premarket session, reflecting positive market sentiment towards the company’s strategic positioning and commitment to affordability.
Photo by Sheila Fitzgerald on Shutterstock
